EASL 2014: Sofosbuvir + Ledipasvir Is Safe and Effective for Relapsers and Hard-to-Treat Hep C Patients
- Category: Experimental HCV Drugs
- Published on Thursday, 10 April 2014 00:00
- Written by Liz Highleyman
A coformulation of sofosbuvir and ledipasvir successfully treated a variety of difficult-to-treat patient populations including people with hepatitis C virus (HCV) genotype 3, patients with decompensated cirrhosis, and people who were not cured with previous sofosbuvir-containing therapy, according to a series of studies presented at the 49thEASL International Liver Congress (EASL 2014) this week in London.